ClinicalTrials.gg
CompletedNCT02251119Updated Sep 29, 2014

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

A Phase 1 interventional study of Tipranavir and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-29.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of the study was to determine if the co-administration of loperamide (LOP) with tipranavir (TPV), ritonavir (RTV), or TPV plus RTV (TPV/r) caused a clinically significant change in the respiratory response to carbon dioxide (CO2), defined as a 10% decrease in the area under the pharmacodynamic effect/time curve or at least a 25% decrease in at least one pharmacodynamic time point.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and willingness to give written in accordance with institutional and federal guidelines and to comply with the nature of the study and the related requirements
  2. Healthy males or females between 18 and 60 years of age inclusive
  3. A (BMI) between 18 and 35 kg/m2
  4. Ability to perform a respiratory depression test
  5. Ability to swallow numerous large capsules without difficulty
  6. In the opinion of the investigator, a reasonable probability for completion of the study
  7. Acceptable laboratory values that indicated adequate baseline organ function were required at the time of screening. Laboratory values were considered to be acceptable if their severity was ≤Grade 1 based on the AIDS Clinical Trials Group Division of AIDS (DAIDS) Grading Scale. All abnormal laboratory values >Grade 1 (e.g., creatinine phosphokinase, amylase, triglycerides) were subject to approval by the clinical monitor or designee
  8. Acceptable medical history, physical examination, , and chest x-ray were required prior to entering the study
  9. Willingness to abstain from alcohol from Day -2 to Day 24. In addition, red wine must not have been ingested within 14 days prior to Day 1 (Visit 2)
  10. Willingness to abstain from ingesting grapefruit, grapefruit juice, Seville oranges, St. John's Wort and Milk Thistle, within 14 days of Day 1 (Visit 2) and for the duration of the study
  11. Willingness to abstain from ingesting garlic supplements, or methylxanthine containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of pharmacokinetic (PK) sampling days (Day 1 [Visit 2], Day 9 [Visit 3], Day 21-22 [Visit 4])
  12. Willingness to abstain from the use of tobacco products for the duration of the study
  13. Nonsmoker
  14. Urine drug screen negative for illegal nonprescription drugs
  15. Negative serology
  16. Negative serology for surface antigen and

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who were of who:

    • Had a positive serum β-human chorionic gonadotropin test at Visit 1, or
    • Had not been using a barrier method for at least 3 months prior to Visit 2 (Day 1), or
    • Were not willing to use a reliable method of double-barrier contraception (such as a diaphragm with spermicidal cream/jelly or condoms with spermicidal foam) during the trial and 30 days after completion/termination of the trial, or
    • Were breast-feeding
  2. Participation in another trial with an medicine for 30 days prior to Day 1 (Visit 2)
  3. Ingestion of any known enzyme-altering drug listed in the protocol 30 days prior to Day 1 (Visit 2)
  4. Ingestion of grapefruit, grapefruit juice, St. John's Wort, Milk Thistle, Seville oranges and red wine within 14 days prior to Day 1 (Visit 2)
  5. Ingestion of garlic supplements or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of PK sampling days (Day 1 [Visit 2], Day 9 [Visit 3], Day 21-22 [Visit 4])
  6. Ingestion of antibiotics within 10 days prior to Day 1 (Visit 2)
  7. Inability to comply with investigator's instructions
  8. History of gastrointestinal, hepatic, or renal disorders within 60 days of study entry
  9. Recent or active alcohol abuse
  10. Current use of tobacco products
  11. Blood or plasma donations within 30 days prior to Day 1 (Visit 2)
  12. Seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/min or >90 beats/min
  13. A history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering TPV or RTV or LOP to the subject
  14. An acute illness within 2 weeks prior to Day 1 (Visit 2)
  15. Current taking of any over-the-counter drug within 7 days prior to Day 1 (Visit 2) or current taking of any prescription drug that, in the opinion of the investigator in consultation with the clinical monitor and pharmacokineticist, might interfere with either the absorption, distribution or metabolism of the test substances
  16. to TPV, RTV, or LOP
  17. Administration of any antidiarrheal agent within 7 days of Day 1 (Visit 2)
  18. Hypersensitivity to sulfonamide drugs
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    TPV

    Administration of LOP on days 1, 9 and 22 Administration of TPV on days 4-9 Administration of TPV/RTV on days 12-22

    Drug: Tipranavir · Drug: Ritonavir · Drug: Loperamide

  • Experimental
    RTV

    Administration of LOP on days 1, 9 and 22 Administration of RTV on days 4-9 Administration of TPV/RTV on days 12-22

    Drug: Tipranavir · Drug: Ritonavir · Drug: Loperamide

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum decrease in the percentage baseline CO2 response slope

    rebreathing test

    Time frame: up to 6 hours on days 1, 9 and 22

  2. Zero-to-six hour area under the curve for the percentage baseline CO2 response slope profile

    Time frame: up to 6 hours on days 1, 9 and 22

Secondary outcomes

  1. Change in the ratio between the diameter of the iris and pupil

    up to 6 hours on days 1, 9 and 22

    Time frame: Pupillary resonse to loperamide

  2. Maximum plasma concentration

    Time frame: up to 75 h after drug administration

  3. Minimum plasma concentration

    Time frame: up to 75 h after drug administration

  4. Time to reach peak or maximum concentration

    Time frame: up to 75 h after drug administration

  5. Terminal half life

    Time frame: up to 75 h after drug administration

  6. Oral clearance

    Time frame: up to 75 h after drug administration

  7. Area under the plasma concentration time curve

    Time frame: up to 75 h after drug administration

  8. Number of subjects with adverse events

    Time frame: up to day 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002 and a primary completion of Jan 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Sep 29, 2014
Start
Jul 2002
Primary completionActual
Jan 2003
Last update
Sep 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02251119
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
Jul 2002
Primary completion
Jan 2003
Last update
Sep 29, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Loperamide

Start the discussion